All In Biotech

Drug Trial Radar · NCT06181786

Study of NAV-240 in Healthy Volunteers

A Randomized, Double-Blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Study to Evaluate Safety, Tolerability, and Pharmacokinetics of NAV-240 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 22, 2023

Primary completion

Sep 4, 2024

Study completion Sep 4, 2024

Sponsor

Lead sponsor
Navigator Medicines, Inc.Industry
Sponsor type
Industry
Collaborators
IMBiologics Corp.
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.

Conditions

  • Healthy

Interventions

  • NAV-240Drug

    Intravenous administration of NAV-240

  • PlaceboDrug

    Intravenous administration of matching placebo for NAV-240

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From the dose of study drug on Day 1 up to Day 71

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syneos Health

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.